BERKELEY, Calif., and VANCOUVER, British Columbia, March 18, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted
immunotherapy for advanced breast cancer, today announces changes to its Board of Directors.
BriaCell is pleased to welcome the appointment of Dr. Rebecca Taub, M.D., and Mr. Vaughn C. Embro-Pantalony to
its Board of Directors. Dr. Saeid Babaei, Mr. Rahoul Sharan, and Mr. Martin Schmieg, members of BriaCell’s Board of Directors, have
resigned from the Board of Directors effective immediately.
The following members of the Board of Directors will be included in BriaCell’s Management Information
Circular for its Annual and Special Meeting of Shareholders to be held on April 10, 2019:
Dr. William V. Williams, Director and Chief Executive Officer;
Mr. Jamieson Bondarenko, Director and Acting Chairman of the Board;
Dr. Charles Wiseman, Director;
Dr. Rebecca Taub, Director;
Mr. Vaughn C. Embro-Pantalony, Director.
Rebecca Taub, M.D., has served as chief medical officer and executive vice president, R&D, and director of
the board for Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics, since 2016. She
acted as chief executive officer and director of the board of privately-held Madrigal Pharmaceuticals, Inc., since inception
through its merger with Synta Pharmaceuticals Corp. Previously, Dr. Taub served as senior vice president, R&D, of VIA
Pharmaceuticals, and as vice president, research, metabolic diseases, at Hoffmann-La Roche where she oversaw clinical development
and drug discovery programs for a number of indications including the conduct of a series of Phase I and II proof of concept
clinical trials. She led drug discovery including target identification, lead optimization and advancement of preclinical
candidates into clinical development. She previously worked at Bristol-Myers Squibb Co. and DuPont Pharmaceuticals Company in a
variety of positions. Prior to becoming a pharmaceutical executive, Dr. Taub was professor of genetics and medicine at the
University of Pennsylvania. She has authored over 120 research articles, served as an assistant professor at the Joslin Diabetes
Center of Harvard Medical School, Harvard University, and was associate investigator with the Howard Hughes Medical Institute. She
received her Doctor of Medicine degree from Yale University School of Medicine and bachelor’s degree from Yale College.
“I am impressed with the technology, and the progress BriaCell has made so far,” Dr. Taub said. “I have been
able to help companies grow and develop therapies during my career. I look forward to sharing my experience with BriaCell's Board
and management team to help BriaCell with its mission of developing novel therapeutics for advanced breast cancer patients who have
a very grim expectation for life.”
Mr. Embro-Pantalony is chairman of the board of Soricimed Biopharma Inc., a private clinical-stage biopharma
company developing targeted cancer therapies. He is also a director of Microbix Biosystems Inc., a leading manufacturer of
viral and bacterial antigens and reagents for the global diagnostics industry, where he also served as president and chief
executive officer from 2012 to 2017. He has held other executive positions in life sciences with responsibility for finance,
business development, strategic planning and information technology including vice president, finance, and chief financial officer
of Novopharm Limited; vice president, information technology, and chief information officer of Bayer Inc.; vice president, finance,
and administration of Bayer Healthcare; and general manager, nitrogen products, for Terra International (Canada) Ltd. He received
his bachelor’s degree from Wilfrid Laurier University and his master of business administration degree from University of Windsor.
He is a Fellow Chartered Professional Accountant and a Chartered Director (C. Dir.) and is Audit Committee Certified (A.C.C.)
through the Directors College, McMaster University.
"I am very excited to be joining BriaCell’s Board. This is a unique opportunity to help BriaCell become a
leading immuno-oncology company by addressing a global unmet need.” stated Mr. Embro-Pantalony.
“Both Dr. Taub and Mr. Embro-Pantalony are widely-regarded forces in the biopharma industry, bringing expert
prowess in clinical oncology, corporate partnership strategy and board governance,” BriaCell’s Director and Acting Chairman of the
Board Jamieson Bondarenko said. “On behalf of BriaCell’s Board of Directors, management team, and shareholders, I would like to
thank Dr. Babaei, Mr. Sharan and Mr. Schmieg for their significant contributions to BriaCell and wish them the very best in their
future ventures.”
"It has been a great privilege to serve as chairman of BriaCell's Board of Directors and be a part of the team
that transformed BriaCell into a leading developer of personalized off-the-shelf immunotherapy since its inception in 2014”, Dr.
Babaei said. “Under Dr. Williams’ leadership, I am proud to report that BriaCell has accomplished a number of important drug
development milestones despite numerous roadblocks in the course of the last few years. I strongly believe that the new Board
members, with their experience, will provide the Company with the corporate strategy and scientific expertise to further advance
the Company’s goals and add shareholder value. As entrepreneurs and trusted leaders, both Dr. Taub and Mr. Embro-Pantalony have
proven track records of success and deep experience in the biopharmaceutical industry. Their experience and insights will be
instrumental in guiding BriaCell through its next chapter of clinical development, particularly as the Company advances Bria-IMT™,
and Bria-OTS™, BriaCell’s novel off-the-shelf personalized immunotherapy for advanced breast cancer, into later stages of
development. I wish BriaCell’s team the very best and look forward to watching them achieve great things in coming years. Finally,
I would like to thank my fellow departing Board members, Mr. Sharan and Mr. Schmieg, for their service and dedication to the
Company. On behalf of the team, we wish them the best in their future endeavors.”
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the
management of cancer.
BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, in a combination
study with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)]. The combination study is listed in
ClinicalTrials.gov as NCT03328026.
BriaCell is developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer.
Bria-OTS™ immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 90% of the patient population, is designed to produce a potent and selective immune
response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with
other personalized immunotherapies.
For additional information on BriaCell, please visit: http://www.BriaCell.com.
Cautionary Note Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains "forward-looking information" within
the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks are more fully described in the Company's public filings
available at www.sedar.com.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of
the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update
or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics Corp.:
Farrah Dean
Manager, Corporate Development
Email: Farrah@BriaCell.com
Phone: 1-888-485-6340
